A waiver on covid-19 intellectual property rights to affect the...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

A waiver on covid-19 intellectual property rights to affect the drug industrys profits

Pharma Tech Outlook | Tuesday, May 10, 2022

The argument against altering the intellectual property system is that intellectual property rights are required to pay the pharma sector for the financial risks it takes when investing in the research and development required to generate new drugs

FREMONT, CA: The majority of experts agree that many people should be vaccinated against Covid-19, but they disagree on the ways to achieve it. The intellectual property rights matter has been at the center of numerous debates; the major issue would be whether firms that created covid-19 vaccines be compelled to make their information available to others who can produce these vaccines and if a waiver of intellectual property rights jeopardizes the future innovation for the sector.

After President Joe Biden expressed support for a temporary waiver on covid-19 vaccine intellectual property rights, this issue surged to the top of the global policy agenda. He now has the support of the US Senate, as well as the World Health Organization, the Independent Scientific Advisory Group for Emergencies in the United Kingdom, Médecins Sans Frontières, and even the Pope. Nonetheless, certain European countries remain obstinately opposed half a year later, and the World Trade Organization's chief has warned that negotiations are frozen, despite involvement from organizations such as Amnesty International and threats of legal action from patients' and health-care workers' representatives.

The argument against altering the intellectual property system is that intellectual property rights are required to pay the pharma sector for the financial risks it takes when investing in the research and development required to generate new drugs. The level of risk faced by drug corporations in the instance of covid-19 vaccinations is controversial because governments supplied a significant portion of research and development money and purchased huge amounts of vaccines in advance. The drug industry, predictably, claims that a waiver would limit the profits that drive new medication development. The emergence of the omicron variant, on the other hand, demonstrates the dangers of maintaining the status quo: increasing vaccination is not just a moral imperative, but also a potential bulwark against the evolution of future variants that are even more contagious, virulent, or immune evasive.

Weekly Brief

Read Also